The drug didn't work. A year later, the paper was flagged.
A trial of a promising GLP-1 drug, exenatide, found no benefit in treating Parkinson's Disease. Over a year later, the paper was flagged after inspectors found serious problems at one of the hospitals that ran it.
Study: The Lancet